Sarcoma Diagnosis and Treatment

This study investigates the role of Myc family proteins in FP-RMS, showing MYCN or MYC dominance in some cases and functional redundancy in others, with both contributing to oncogenic properties.

This study shows ATRX loss in sarcomas correlates with poor outcomes and identifies TEAD inhibition as a potential therapy for ATRX-deficient tumors.

This study identifies three proteogenomic subtypes of soft tissue leiomyosarcoma with distinct molecular features and clinical outcomes, suggesting potential therapeutic targets.

This paper develops a new mouse model of CIC::DUX4 sarcoma and identifies Minnelide as a selective inhibitor effective in preclinical models.

This paper develops Auto-RS, a computational classifier using autophagy gene expression to predict osteosarcoma prognosis and identify therapeutic vulnerabilities.

The paper shows that K252a treatment delays Ewing sarcoma tumor growth and reduces Trk, PI3K, and IGF1R expression and activity, with combined treatment more effective than single agents.

This study shows Riluzole induces apoptosis in osteosarcoma by upregulating EGR1, which interacts with Yap/p73 to enhance Bax expression and promote cell death.

This study identifies neural crest cells as the origin of Ewing sarcoma by developing a zebrafish model and showing EWSR1::FLI1 reprograms these cells to a mesoderm-like state.

This study shows NR0B1 alters the 9-cis-retinoic acid response in Ewing Sarcoma cells by modulating nuclear receptor activity, suggesting NR0B1 inhibition could enhance retinoid therapy.

This study shows that CK2 inhibitor CX-4945 targets EWS-FLI1 and reduces tumor growth and metastasis in Ewing Sarcoma models.

This paper investigates how EWS's RNA-binding domains interact with its low-complexity domain to influence condensate formation, revealing electrostatic and residue-specific interactions that underlie EWS self-association.

The paper experimentally evolves resistance in Ewings sarcoma cell lines to identify gene expression signatures predicting collateral drug responses, validated in an independent cell line.

This study shows that blocking IL-6 signaling in DDLPS reduces MDM2 oncogenicity through alternative splicing, suggesting a potential therapeutic target.

This study develops an immunocompetent mouse model of liposarcoma that recapitulates human tumor subtypes and immune features, enabling preclinical immunotherapy research.

This study shows that PAX3-FOXO1 drives metabolic vulnerabilities in rhabdomyosarcoma, making these cells sensitive to methotrexate.

This paper demonstrates that Riluzole enhances osteosarcoma radiosensitivity to single high dose radiotherapy by targeting both tumor cells and angiogenic vasculature.

This study identifies CXADR as a driver of Ewing sarcoma metastasis and shows that targeting AKT signaling with Capivasertib enhances chemotherapy efficacy in CXADR-high tumors.

This paper identifies MAPK signaling and MYC-driven suppression of p21 as mechanisms of vincristine resistance in fusion-negative rhabdomyosarcoma and shows that dual targeting of MAPK and BCL-XL pathways overcomes resistance.

This study identifies RUNX2 as a druggable target in fusion-positive rhabdomyosarcoma, showing its inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and reduces tumor growth.

This study compares immunogenic features between undifferentiated soft tissue sarcoma and myxofibrosarcoma, finding differences in T cell and macrophage infiltration and their prognostic significance.

The paper identifies PAX3::FOXO1's pioneer function through partial/homeobox motif recognition and its role in initiating neural transcriptional programs in rhabdomyosarcoma.

This study uses single-cell and spatial transcriptomics to analyze tumor microenvironment heterogeneity in osteosarcomas, identifying distinct cellular states and spatial niches.

This paper identifies that SP-2509 and SP-2577, LSD1 inhibitors, induce cell death in Ewing sarcoma through Fe-S cluster disruption, independent of LSD1 inhibition.

The paper identifies distinct transcriptional programs in Ewing sarcoma driven by EWS::FLI1 fusions and shows their variability across tumors and cell lines.

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

This study shows that EphA7 and ephrin-A5 regulate rhabdomyosarcoma proliferation, with ephrin-A5 being a potential therapeutic target for differentiation therapy.

This study classifies retroperitoneal liposarcoma into two subtypes using molecular features, showing improved survival outcomes for one subtype based on biomarkers LEP and PTTG1.

This paper identifies romidepsin as a promising repurposed drug for osteosarcoma using 3D spheroid models, showing efficacy against metastatic cells and outperforming other HDIs.

This study shows that reduced EWSR1::ETS activity in Ewing sarcoma promotes immune evasion via the tryptophan-kynurenine-AHR axis, leading to worse clinical outcomes and tumor progression.

This study shows that varying levels of PAX3::FOXO1 protein affect cell state and epigenetic heterogeneity in rhabdomyosarcoma.